Payment overview · 2025
General Payments
$1,031.09
62 reported records · 18 companies
Healthcare provider profile · identity verified
Randy James Grellner, DO
Allopathic & Osteopathic Physicians|Family Medicine · CUSHING, OK · NPI 1356364376
Verified facts
What the public records show
CMS Open Payments records show Randy James Grellner, DO received $1,031.09 in general payments during 2025 across 62 reported records.
ABBVIE INC. accounted for 15.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.57 | 15.4% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $114.52 | 11.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.33 | 10.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $100.44 | 9.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.40 | 9.3% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $77.28 | 7.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.46 | 7.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.17 | 4.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.07 | 3.9% | 2 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.65 | 3.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.42 | 3.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.66 | 3.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.12 | 2.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $23.14 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.07 | 1.9% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.19 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.23 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.37 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,031.09 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $122.63 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $100.44 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $84.83 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $77.28 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $68.96 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.47 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $62.47 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $58.31 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $58.31 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.71 | 9 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $45.56 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.55 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.42 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.58 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 445 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 391 | 82 |
| Gabapentin | Gabapentin | 312 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 74 |
| Potassium Chloride | Potassium Chloride | 278 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 274 | 61 |
| Lisinopril | Lisinopril | 260 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 63 |
| Furosemide | Furosemide | 225 | 59 |
| Ropinirole Hcl | Ropinirole Hcl | 217 | 40 |
| Omeprazole | Omeprazole | 209 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 55 |
| Losartan Potassium | Losartan Potassium | 189 | 48 |
| Metformin Hcl | Metformin Hcl | 185 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 180 | 40 |
| Simvastatin | Simvastatin | 174 | 45 |
| Montelukast Sodium | Montelukast Sodium | 170 | 35 |
| Meloxicam | Meloxicam | 168 | 43 |
| Tramadol Hcl | Tramadol Hcl | 164 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 35 |
| Carvedilol | Carvedilol | 155 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 39 |
| Pregabalin | Pregabalin | 130 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 34 |
| Alprazolam | Alprazolam | 117 | 36 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 112 | 25 |
| Donepezil Hcl | Donepezil Hcl | 111 | 27 |
| Prednisone | Prednisone | 109 | 47 |
| Eliquis | Apixaban | 108 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 28 |
| Methylprednisolone | Methylprednisolone | 104 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 23 |
| Allopurinol | Allopurinol | 98 | 23 |
| Mounjaro | Tirzepatide | 98 | 17 |
| Estradiol | Estradiol | 95 | 23 |
| Sertraline Hcl | Sertraline Hcl | 95 | 21 |
| Famotidine | Famotidine | 92 | 16 |
| Cefdinir | Cefdinir | 91 | 68 |
| Azithromycin | Azithromycin | 88 | 78 |
| Ozempic | Semaglutide | 78 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 19 |
| Aripiprazole | Aripiprazole | 67 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 67 | suppressed |
| Jardiance | Empagliflozin | 67 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Celecoxib | Celecoxib | 63 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 18 |
| Spironolactone | Spironolactone | 63 | 13 |
| Trulicity | Dulaglutide | 63 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 18 |
| Warfarin Sodium | Warfarin Sodium | 59 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 58 | 11 |
| Propranolol Hcl | Propranolol Hcl | 56 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 12 |
| Atenolol | Atenolol | 53 | 14 |
| Trazodone Hcl | Trazodone Hcl | 53 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 20 |
| Finasteride | Finasteride | 51 | 16 |
| Baclofen | Baclofen | 49 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 11 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 48 | 11 |
| Valsartan | Valsartan | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 12 |
| Glimepiride | Glimepiride | 47 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 40 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 21 |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Metronidazole | Metronidazole | 38 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 16 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 12 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | 12 |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 11 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Modafinil | Modafinil | 32 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 32 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Progesterone | Progesterone, Micronized | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Methadone Hcl | Methadone Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 14 |
| Cephalexin | Cephalexin | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Victoza 2-Pak | Liraglutide | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,031.09 · 62 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, APLENZIN, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, INSPIRE, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, WELLBUTRIN, WaveWriter Alpha Prime 16, XYOSTED, YUPELRI, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error